Oramed Pharmaceuticals (ORMP) Change in Acquisitions & Divestments (2010 - 2026)

Oramed Pharmaceuticals (ORMP) has 16 years of Change in Acquisitions & Divestments data on file, last reported at $3.5 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 87.62% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$22.1 million (down 119.95% YoY) and the FY2025 annual result came in at $2.9 million, down 97.05% from the prior year.
• Change in Acquisitions & Divestments improved to $3.5 million in Q1 2026, from -$47.6 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $124.2 million in Q3 2022 to a low of -$47.6 million in Q4 2025.
• A 5-year average of $17.8 million and a median of $4.8 million in 2022 frame the typical range for Change in Acquisitions & Divestments.
• The widest YoY moves for Change in Acquisitions & Divestments: up 2370.05% in 2025, down 237.0% in 2025.
• Tracing ORMP's Change in Acquisitions & Divestments over 5 years: stood at $50.2 million in 2022, then tumbled by 98.71% to $650000.0 in 2023, then soared by 9154.15% to $60.2 million in 2024, then plunged by 179.11% to -$47.6 million in 2025, then surged by 107.4% to $3.5 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $3.5 million (Q1 2026), -$47.6 million (Q4 2025), and $49.4 million (Q3 2025), per Business Quant data.